Marker Therapeutics (MRKR) Enterprise Value (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Enterprise Value of -$15.6 million for Q1 2026, down 14.04% year-over-year from -$18.2 million in Q1 2025, and up 8.37% quarter-over-quarter from -$17.0 million in Q4 2025.
Marker Therapeutics (MRKR) Enterprise Value (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Enterprise Value for 17 consecutive years, with -$15.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 14.04% year-over-year to -$15.6 million; the TTM figure through Mar 2026 stood at -$15.6 million (down 14.04% YoY), while the FY2025 annual figure was -$17.0 million, up 11.2% from the prior year.
- Enterprise Value improved to -$15.6 million in Q1 2026 per MRKR's latest filing, from -$17.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$6.4 million in Q1 2023 and bottomed at -$28.8 million in Q1 2022.
- Historically, Enterprise Value has averaged -$15.7 million across 5 years, with a median of -$15.6 million in 2026.
- Annual changes were most pronounced in 2023 — Enterprise Value jumped 77.79% — and 2025, when it sank 111.01%.
- Marker Therapeutics' Enterprise Value stood at -$11.8 million in 2022, then declined by 28.26% to -$15.1 million in 2023, then declined by 27.01% to -$19.2 million in 2024, then grew by 11.2% to -$17.0 million in 2025, then rose by 8.37% to -$15.6 million in 2026.
- Business Quant data shows MRKR's Enterprise Value at -$15.6 million in Q1 2026, -$17.0 million in Q4 2025, and -$19.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | -11.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.62 Mn |
| Dec 31, 2025 | -17.04 Mn |
| Sep 30, 2025 | -18.99 Mn |
| Jun 30, 2025 | -11.86 Mn |
| Mar 31, 2025 | -13.69 Mn |
| Dec 31, 2024 | -19.19 Mn |
| Sep 30, 2024 | -9.00 Mn |
| Jun 30, 2024 | -7.80 Mn |
| Mar 31, 2024 | -11.32 Mn |
| Dec 31, 2023 | -15.11 Mn |
| Sep 30, 2023 | -17.47 Mn |
| Jun 30, 2023 | -18.10 Mn |
| Mar 31, 2023 | -6.40 Mn |
| Dec 31, 2022 | -11.78 Mn |
| Sep 30, 2022 | -18.08 Mn |
| Jun 30, 2022 | -25.82 Mn |
| Mar 31, 2022 | -28.82 Mn |
| Dec 31, 2021 | -43.50 Mn |
| Sep 30, 2021 | -48.70 Mn |
| Jun 30, 2021 | -57.20 Mn |